Hawaii 2022 Regular Session

Hawaii Senate Bill SB322 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	THE SENATE S.B. NO. 322 THIRTY-FIRST LEGISLATURE, 2021 STATE OF HAWAII A BILL FOR AN ACT relating to prescription drugs. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
2	2
3	3	THE SENATE S.B. NO. 322
4	4	THIRTY-FIRST LEGISLATURE, 2021
5	5	STATE OF HAWAII
6	6
7	7	THE SENATE
8	8
9	9	S.B. NO.
10	10
11	11	322
12	12
13	13	THIRTY-FIRST LEGISLATURE, 2021
14	14
15	15
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31	A BILL FOR AN ACT
32	32
33	33
34	34
35	35
36	36
37	37	relating to prescription drugs.
38	38
39	39
40	40
41	41
42	42
43	43	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
44	44
45	45
46	46
47	47	SECTION 1. Chapter 431R, Hawaii Revised Statutes, is amended by adding a new section to be appropriately designated and to read as follows: "§431R- Mandatory notification of prescription drug price increases. (a) A manufacturer of a prescription drug with a wholesale acquisition cost of more than $40 for a course of therapy shall notify each prescription drug benefit plan and pharmacy benefit manager of any planned price increase if that increase will result in a sixteen per cent or more increase in the wholesale acquisition cost of the prescription drug over any two-year period. (b) The notice required by subsection (a) shall: (1) Be provided in writing at least sixty days prior to the planned effective date of the price increase; and (2) Include: (A) The date the price increase shall take effect; (B) The current wholesale acquisition cost of the prescription drug; (C) The dollar amount of the future price increase in the wholesale acquisition cost of the prescription drug; and (D) A statement regarding whether a change or improvement in the drug necessitates the price increase, and if so, a description of the change or improvement. (c) The insurance commissioner shall post on the website of the department of commerce and consumer affairs the names and addresses of the prescription drug benefit plans and pharmacy benefit managers required to receive notice pursuant to this section." SECTION 2. Section 431R-1, Hawaii Revised Statutes, is amended by adding a new definition to be appropriately inserted and to read as follows: ""Course of therapy" means: (1) The recommended daily dosage units of a prescription drug for thirty days, pursuant to its prescribing label as approved by the federal Food and Drug Administration; or (2) The recommended daily dosage units of a prescription drug pursuant to its prescribing label for a normal course of treatment that is less than thirty days, as approved by the federal Food and Drug Administration." SECTION 3. Section 431R-4, Hawaii Revised Statutes, is amended by amending subsection (a) to read as follows: "(a) No later than March 31 of each calendar year, each prescription drug benefit plan, health benefits plan under chapter 87A, and pharmacy benefit manager shall file with the insurance commissioner, in [such] a form and detail as the insurance commissioner shall prescribe, a report for the preceding calendar year stating that the pharmacy benefit manager or prescription drug benefit plan is in compliance with this chapter. The report shall fully disclose the amount, terms, and conditions relating to copayments, reimbursement options, and other payments associated with a prescription drug benefit plan. Each report shall disclose an address that will be posted on a public website for purposes of receiving notifications pursuant to section 431R- ." SECTION 4. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored. SECTION 5. This Act shall take effect upon its approval. INTRODUCED BY: _____________________________
48	48
49	49	SECTION 1. Chapter 431R, Hawaii Revised Statutes, is amended by adding a new section to be appropriately designated and to read as follows:
50	50
51	51	"§431R- Mandatory notification of prescription drug price increases. (a) A manufacturer of a prescription drug with a wholesale acquisition cost of more than $40 for a course of therapy shall notify each prescription drug benefit plan and pharmacy benefit manager of any planned price increase if that increase will result in a sixteen per cent or more increase in the wholesale acquisition cost of the prescription drug over any two-year period.
52	52
53	53	(b) The notice required by subsection (a) shall:
54	54
55	55	(1) Be provided in writing at least sixty days prior to the planned effective date of the price increase; and
56	56
57	57	(2) Include:
58	58
59	59	(A) The date the price increase shall take effect;
60	60
61	61	(B) The current wholesale acquisition cost of the prescription drug;
62	62
63	63	(C) The dollar amount of the future price increase in the wholesale acquisition cost of the prescription drug; and
64	64
65	65	(D) A statement regarding whether a change or improvement in the drug necessitates the price increase, and if so, a description of the change or improvement.
66	66
67	67	(c) The insurance commissioner shall post on the website of the department of commerce and consumer affairs the names and addresses of the prescription drug benefit plans and pharmacy benefit managers required to receive notice pursuant to this section."
68	68
69	69	SECTION 2. Section 431R-1, Hawaii Revised Statutes, is amended by adding a new definition to be appropriately inserted and to read as follows:
70	70
71	71	""Course of therapy" means:
72	72
73	73	(1) The recommended daily dosage units of a prescription drug for thirty days, pursuant to its prescribing label as approved by the federal Food and Drug Administration; or
74	74
75	75	(2) The recommended daily dosage units of a prescription drug pursuant to its prescribing label for a normal course of treatment that is less than thirty days, as approved by the federal Food and Drug Administration."
76	76
77	77	SECTION 3. Section 431R-4, Hawaii Revised Statutes, is amended by amending subsection (a) to read as follows:
78	78
79	79	"(a) No later than March 31 of each calendar year, each prescription drug benefit plan, health benefits plan under chapter 87A, and pharmacy benefit manager shall file with the insurance commissioner, in [such] a form and detail as the insurance commissioner shall prescribe, a report for the preceding calendar year stating that the pharmacy benefit manager or prescription drug benefit plan is in compliance with this chapter. The report shall fully disclose the amount, terms, and conditions relating to copayments, reimbursement options, and other payments associated with a prescription drug benefit plan. Each report shall disclose an address that will be posted on a public website for purposes of receiving notifications pursuant to section 431R- ."
80	80
81	81	SECTION 4. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.
82	82
83	83	SECTION 5. This Act shall take effect upon its approval.
84	84
85	85
86	86
87	87	INTRODUCED BY: _____________________________
88	88
89	89	INTRODUCED BY:
90	90
91	91	_____________________________
92	92
93	93
94	94
95	95
96	96
97	97	Report Title: Department of Commerce and Consumer Affairs; Prescription Drugs; Price Increases; Notification; Insurance Commissioner Description: Requires that if a proposed increase in the wholesale price of certain drugs would result in a 16 per cent or more price increase over a two-year period, the drug manufacturer shall notify various drug insurance providers. The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
98	98
99	99
100	100
101	101
102	102
103	103	Report Title:
104	104
105	105	Department of Commerce and Consumer Affairs; Prescription Drugs; Price Increases; Notification; Insurance Commissioner
106	106
107	107
108	108
109	109	Description:
110	110
111	111	Requires that if a proposed increase in the wholesale price of certain drugs would result in a 16 per cent or more price increase over a two-year period, the drug manufacturer shall notify various drug insurance providers.
112	112
113	113
114	114
115	115
116	116
117	117
118	118
119	119	The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.